Outlook 2022
Annual industry ranking and forecast
Policy & Regulation
Big-picture policy developments – a deeper look at Operation Warp Speed in the US, exploration of the FDA’s new ‘D’ meetings and a review of changes for improved access to hearing aid technologies.
Operation Warp Speed: What The Logo Can Tell Us About Successful Pandemic Preparedness
Operation Warp Speed’s seal was a combination of ’70s design, au courant clip art, and 18th Century militarism, but just like the oddly assembled organization that it represented, the thing worked.
Listen Up! Big Things Happening In The World Of Audiology
From innovation to legislation, the US audiology market is being shaped by cutting-edge technology from device makers and legislation from the Biden administration to get more hearing aids to those that need them.
When It Comes To Sponsor Meetings, FDA Is Getting A ‘D’
New ‘Type D’ meetings will be added as part of PDUFA VII, one of a spate of changes under the next version of the user fee program that will begin in October 2022.
New EU Clinical Trials System Could Support Patient Recruitment
The EU research-based pharma industry is exploring partnerships to develop an app that would extract data from the new Clinical Trial Information System and convert it into lay format to guide patients interested in participating in studies.
Chapter sponsored by:
The Lasting Impact Of The Pandemic On Pharmacovigilance
Despite the critical importance of pharmacovigilance (PV) activities, two years ago it was a concept with which most people outside the life sciences space were largely unfamiliar. Since the onset of the COVID-19 pandemic, however, this has changed immensely.
Outlook 2022 e-Book
Download a PDF copy of the Outlook 2022 collection, including Scrip 100 league tables.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.